干癣性关节炎市场：KOL 洞察

本报告检视了全球干癣性关节炎（PsA）市场，从经过验证的安全性和有效性的抗 TNF 药物的持续优势，到Bimzelx作为利基疗法的潜力，到 Skyrizi/Tremfya 在皮肤状况管理方面的卓越功效，研究了当前和新兴的治疗方法，并对影响当今 PsA 管理临床决策的策略偏好和实践提供了宝贵的见解。

目录

执行摘要

干癣关节炎目前和未来的治疗演算法

研究目的

核准的药物

• 抗肿瘤坏死因子剂
  • 主要见解摘要
• 白血球介素17抑制剂
  • Cosentyx（secukinumab; Novartis）
  • Taltz（ixekizumab，ixekizumab; Lilly）
  • Bimzerx（bimekizumab; UCB）
• Interleukin-12/23 和 interleukin-23 抑制剂
  • Stelara (ustekinumab; Johnson & Johnson)
  • Skyrizi (risankizumab; AbbVie/Boehringer Ingelheim)
  • Tremfya (guselkumab; Johnson & Johnson)
• Janus 激酶（JAK）抑制剂
  • Xeljanz (tofacitinib; Pfizer)
  • Rinvoq (upadacitinib; AbbVie)
• T细胞活化抑制剂
  • Orencia（abatacept; Bristol Myers Squibb）
• 4型环核苷酸磷酸二酯酶抑制剂
  • Otezla（apremilast; Amgen）

在研药物

• 白血球介素17抑制剂
  • Brodalumab（AstraZeneca/LEO Pharma）
  • Izoquivep（Afibody/Aceririn）和 Sonelokimab（MoonLake Immunotherapeutics）
• 白血球介素23抑制剂
  • Ilumya/Ilmetri（tildrakizumab、Almirall/Sun Pharmaceutical）
• 酪胺酸激酶 2（TYK2）抑制剂
  • Sotiktu（deucravacitinib; Bristol Myers Squibb）
  • TAK-279（Takeda）
• Kv1.3钾通道抑制剂
  • si-544（选择）

干癣关节炎治疗的未来趋势与可能性

附录

KOL报表

Insights from leading KOLs on the evolving landscape of psoriatic arthritis (PsA) treatment. From the continued dominance of anti-TNFs due to their proven safety and efficacy to Bimzelx's potential as a niche treatment and Skyrizi/Tremfya's superior efficacy in managing skin symptoms, this report examines current and emerging therapies providing valuable insights into the strategic preferences and practices that are shaping clinical decisions in PsA management today.

Table of Contents

Executive summary

Current and future treatment algorithm for psoriatic arthritis

Research objectives

Approved drugs (105)

• Anti-tumour necrosis factor agents
  • Key insights summary
• Interleukin-17 inhibitors
  • Cosentyx (secukinumab; Novartis)
  • Taltz (ixekizumab; Lilly)
  • Bimzelx (bimekizumab; UCB)
• Interleukin-12/23 and interleukin-23 inhibitors
  • Stelara (ustekinumab; Johnson & Johnson)
  • Skyrizi (risankizumab; AbbVie/Boehringer Ingelheim)
  • Tremfya (guselkumab; Johnson & Johnson)
• Janus kinase (JAK) inhibitors
  • Xeljanz (tofacitinib; Pfizer)
  • Rinvoq (upadacitinib; AbbVie)
• T-cell activation inhibitors
  • Orencia (abatacept; Bristol Myers Squibb)
• Type 4 cyclic nucleotide phosphodiesterase inhibitors
  • Otezla (apremilast; Amgen)

Pipeline drugs

• Interleukin-17 inhibitors
  • Brodalumab (AstraZeneca/LEO Pharma)
  • Izokibep (Affibody/ACELYRIN) and sonelokimab (MoonLake Immunotherapeutics)
• Interleukin-23 inhibitors
  • Ilumya/Ilumetri (tildrakizumab; Almirall/Sun Pharmaceutical)
• Tyrosine kinase 2 (TYK2) inhibitors
  • Sotyktu (deucravacitinib; Bristol Myers Squibb)
  • TAK-279 (Takeda)
• Kv1.3 potassium channel inhibitor
  • si-544 (selectION)

Future trends and opportunities in psoriatic arthritis treatment

Appendix

• KOL details
  • KOLs from North America
  • KOLs from Europe

KOL Bulletins